ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial†

Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group

(2013) Diana Wongso et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis

(2013) Nicole Skoetz et al.   LANCET ONCOLOGY

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

(2013) Anas Younes et al.   LANCET ONCOLOGY

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

(2012) Alden A. Moccia et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma

(2012) David W. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

(2012) Andreas Engert et al.   LANCET

Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group

(2011) Peter Borchmann et al.   JOURNAL OF CLINICAL ONCOLOGY

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

(2011) Simonetta Viviani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

(2009) Andreas Engert et al.   JOURNAL OF CLINICAL ONCOLOGY

ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

(2009) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY